Navigation Links
Pill Reduces Relapses in MS Patients
Date:4/15/2008

First oral drug could benefit many with the autoimmune disease, researchers say

TUESDAY, April 15 (HealthDay News) -- The first pill designed to reduce the number of attacks in people with multiple sclerosis appears to be effective in early tests, Italian researchers report.

The pill was effective in preventing relapses in more than 60 percent of patients who took the pill for three years, according to research that was expected to be presented April 15 the American Academy of Neurology annual meeting, in Chicago.

"All of the current treatments for MS must be injected, so having a pill you can swallow with a glass of water would be a welcome improvement for many people," lead researcher Dr. Giancarlo Comi, from Vita-Salute San Raffaele University in Milan, said in a prepared statement.

In the study, Comi's team treated 281 people with relapsing MS with FTY720 (fingolimod) or a placebo. After six months, two-thirds of the patients who received FTY720 had more than 50 percent fewer relapses, compared with those receiving placebo.

During the three years of the trial, more than 67 percent of the 173 people receiving FTY720 were free of relapses. In addition, 89 percent of the patients were free of disease activity and 75 percent did not develop new lesions or see their lesions enlarge. This was confirmed by MRI scans, the researchers stated.

"The first-line treatments for MS, beta interferon and glatiramer acetate, reduce the relapse rate by only about 30 percent, so this is a significant development for people with MS," Comi said in a statement.

The most commonly reported side effects of FTY720 were headache, flu and cold symptoms.

The drug works by binding to receptors on immune cells, isolating them in the lymph nodes, thereby reducing their ability to cause the damage associated with MS symptoms.

The study was paid for by Novartis Pharma AG, maker of FTY720.

One expert thinks this preliminary data is encouraging, but a lot more needs to be done to prove the drug's effectiveness.

"This is a new drug that has a very strong scientific rationale why it could work," said Dr. John Richert, executive vice president of the National Multiple Sclerosis Society. "Certainly, everything we've seen so far continues to keep us optimistic."

Richert noted that over three years, 77 patients receiving the drug dropped out of the study. "You're left wondering if a more severe adverse event led to the dropouts," he said.

The six-month data where the drug was tested against placebo looks promising, Richert said. "If this turns out to be a safe oral drug that has substantial benefit, that will be very important for many people with MS," he added.

More information

For more on MS, visit the National Multiple Sclerosis Society.



SOURCES: John Richert, M.D., executive vice president, National Multiple Sclerosis Society, New York City; April 15, 2008, presentation, American Academy of Neurology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent
2. Essential nutrient found in eggs reduces risk of breast cancer by 24 percent
3. Psychological intervention reduces postembolization pain
4. Aspirin Reduces Asthma Risk Among Older Women
5. Low-Fat Dairy Reduces High Blood Pressure Risk
6. HPV vaccine reduces abnormal pap test results
7. Renal Assist Device reduces risk of death from acute kidney failure
8. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
9. Restricting kids video time reduces obesity, randomized trial shows
10. Low-intensity exercise reduces fatigue symptoms by 65 percent, study finds
11. Super Prostate Product - More Beta-sitosterol, all-natural Best Prostate(TM) Formula for Enlarged Prostate and BPH - Increases Urine Flow, Reduces Waking and Improves Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pill Reduces Relapses in MS Patients
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to popular perception, a ... declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found ... in the United States. The study, Trends in Fighting and Violence Among ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its ... that the full potential of specialty and orphan brands can only be achieved when ... , “The Unifying Effect is at the heart of a true partnership between our ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry ... O2X , an active lifestyle company that provides Human Performance Training and education ... police offers, first responders, military officers and others in service through the development ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... in the category of International Trade, the UK’s most prestigious award for business ... which represents 95% of total revenues and has grown by a total of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... in hopes of squashing a global crisis with solution to peace plan. Yisrayl says war ... because the plan is given by the Creator Himself. , Yisrayl says war drums ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
Breaking Medicine Technology: